Your browser doesn't support javascript.
loading
Identification of a Novel Bcl-2 Inhibitor by Ligand-Based Screening and Investigation of Its Anti-cancer Effect on Human Breast Cancer Cells.
Wen, Mei; Deng, Zhen-Ke; Jiang, Shi-Long; Guan, Yi-di; Wu, Hai-Zhou; Wang, Xin-Luan; Xiao, Song-Shu; Zhang, Yi; Yang, Jin-Ming; Cao, Dong-Sheng; Cheng, Yan.
Affiliation
  • Wen M; Xiangya School of Pharmaceutical Sciences, Central South University, Changsha, China.
  • Deng ZK; Xiangya School of Pharmaceutical Sciences, Central South University, Changsha, China.
  • Jiang SL; Xiangya School of Pharmaceutical Sciences, Central South University, Changsha, China.
  • Guan YD; Xiangya School of Pharmaceutical Sciences, Central South University, Changsha, China.
  • Wu HZ; Xiangya School of Pharmaceutical Sciences, Central South University, Changsha, China.
  • Wang XL; Translational Medicine R&D Center, Institute of Biomedical and Health Engineering, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen, China.
  • Xiao SS; Department of Gynecology and Obstetrics, The Third Xiangya Hospital, Central South University, Changsha, China.
  • Zhang Y; Department of Pharmacology, College of Pharmaceutical Sciences, Soochow University, Suzhou, China.
  • Yang JM; Department of Pharmacology, The Penn State Hershey Cancer Institute, The Pennsylvania State University College of Medicine and Milton S Hershey Medical Center, Hershey, PA, United States.
  • Cao DS; Xiangya School of Pharmaceutical Sciences, Central South University, Changsha, China.
  • Cheng Y; Department of Dermatology, Xiangya Hospital, Central South University, Changsha, China.
Front Pharmacol ; 10: 391, 2019.
Article de En | MEDLINE | ID: mdl-31057406
ABSTRACT
Bcl-2 family protein is an important factor in regulating apoptosis and is associated with cancer. The anti-apoptotic proteins of Bcl-2 family, such as Bcl-2, are overexpression in numerous tumors, and contribute to cancer formation, development, and therapy resistance. Therefore, Bcl-2 is a promising target for drug development, and several Bcl-2 inhibitors are currently undergoing clinical trials. In this study, we carried out a QSAR-based virtual screening approach to develop potential Bcl-2 inhibitors from the SPECS database. Surface plasmon resonance (SPR) binding assay was performed to examine the interaction between Bcl-2 protein and the screened inhibitors. After that, we measured the anti-tumor activities of the 8 candidate compounds, and found that compound M1 has significant cytotoxic effect on breast cancer cells. We further proved that compound M1 downregulated Bcl-2 expression and activated apoptosis by inducing mitochondrial dysfunction. In conclusion, we identified a novel Bcl-2 inhibitor by QSAR screening, which exerted significant cytotoxic activity in breast cancer cells through inducing mitochondria-mediated apoptosis.
Mots clés

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Type d'étude: Diagnostic_studies / Prognostic_studies / Screening_studies Langue: En Journal: Front Pharmacol Année: 2019 Type de document: Article Pays d'affiliation: Chine

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Type d'étude: Diagnostic_studies / Prognostic_studies / Screening_studies Langue: En Journal: Front Pharmacol Année: 2019 Type de document: Article Pays d'affiliation: Chine